Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million
Neurogene focused on advancing Phase 1/2 trial for NGN-401, a differentiated clinical stage gene therapy to treat Rett syndrome using its EXACT technology; interim... Read more.
micromobility.com Inc. to Address Nasdaq Delisting Notice; Postpones Special Meeting and Withdraws Reverse Split Request
NEW YORK–(BUSINESS WIRE)–micromobility.com Inc. (“micromobility.com” or the “Company”) (Nasdaq: MCOM), a leader in innovative urban transportation... Read more.
Kiana Analytics Selected by Chevron Technology Ventures for Catalyst Program
SUNNYVALE, Calif.–(BUSINESS WIRE)–#B2B—Kiana Analytics, a leading provider of hardware-agnostic solutions for Connected Worker data analytics in... Read more.
Ionic Mineral Technologies Partners With ANDRITZ on Nano-silicon Mass Production for Electric Vehicles
PROVO, Utah–(BUSINESS WIRE)–#IonicMT—Ionic Mineral Technologies, a pioneering US-based producer of nano-silicon anode powders, has partnered with... Read more.
CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication Adherence
CareDx Expands Reach of its Transplant Pharmacy Services by Offering NFT Patients Help in Navigating the Complexity of Immunosuppression Medications and Adherence... Read more.
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis
Statistically significant improvement from baseline observed in investigator-assessed Eczema Area and Severity Index (EASI, p=0.0006) and Investigator Global Assessment... Read more.
Social Links and TechBiz Forense Digital redouble efforts to expand Forensic Technology services in Brazil and Latin America
NEW YORK–(BUSINESS WIRE)–Social Links, a leading open-source intelligence (OSINT) software provider, strengthens its strategic partnership with TechBiz... Read more.
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults
Acceptance based on results from multiple Phase 3 trials If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults The... Read more.
Accenture Reports First-Quarter Fiscal 2024 Results
Revenues of $16.2 billion, an increase of 3% in U.S. dollars and 1% in local currency GAAP operating margin of 15.8%, compared to 16.5% in the first quarter of fiscal... Read more.
Permian Resources Corporation Announces Secondary Public Offering of Class A Common Stock
MIDLAND, Texas–(BUSINESS WIRE)–Permian Resources Corporation (“Permian Resources” or the “Company”) (NYSE: PR) today announced the commencement... Read more.